Kite Pharma (KITE) announced that it has completed enrollment in the mid-stage portion of its Phase 1/2 clinical trial, ZUMA-1, assessing lead product candidate, Breakthrough Therapy-tagged KTE-C19, in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The primary endpoint of the Phase 2 is overall response rate at month 12. According to, the estimated study completion date is March 2017. KITE shares though are down more than 6% in early trading, feeling the negative impact of the Juno Therapeutics (JUNO) setback.